June 2, 2024

Adjunctive Statistical Standardization of Adjuvant Estrogen Receptor and Progesterone Receptor in Canadian Cancer Trials Group MA.27 Postmenopausal Breast Cancer Trial of Exemestane Versus Anastrozole

Key Points

Key points are not available for this paper at this time.

Abstract

ASCO/College of American Pathologists guidelines recommend reporting estrogen receptor (ER) and progesterone receptor (PgR) as positive with (1%-100%) staining. Statistically standardized quantitated positivity could indicate differential associations of positivity with breast cancer outcomes.

AI से पूछें

Bookmark

Cite This Study

Chapman et al. (Sun,) studied this question.

synapsesocial.com/papers/68e66854b6db6435875f4d25 https://doi.org/https://doi.org/10.1200/jco.24.00835

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Automated image analysis for high‐throughput quantitative detection of ER and PR expression levels in large‐scale clinical studies: The TEAM Trial Experience2009 · 56 citations
2An Analysis of Transformations1964 · 15,093 citations
3Exemestane Versus Anastrozole in Postmenopausal Women With Early Breast Cancer: NCIC CTG MA.27—A Randomized Controlled Phase III Trial2013 · 260 citations
4Advances in quantitative immunohistochemistry and their contribution to breast cancer2020 · 24 citations
5Evidence for bimodal distribution of breast carcinoma ER and PgR values quantitated by enzyme immunoassay1993 · 8 citations

AI से पूछें

Bookmark